Fred Alger Management Inc. cut its stake in shares of Glaukos Corporation (NYSE:GKOS) by 25.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,000 shares of the medical instruments supplier’s stock after selling 7,000 shares during the period. Fred Alger Management Inc. owned about 0.06% of Glaukos Corporation worth $871,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Capital World Investors lifted its stake in Glaukos Corporation by 17.1% during the 2nd quarter. Capital World Investors now owns 2,740,000 shares of the medical instruments supplier’s stock valued at $113,628,000 after acquiring an additional 400,000 shares in the last quarter. Sandhill Capital Partners LLC lifted its stake in Glaukos Corporation by 5.0% during the 2nd quarter. Sandhill Capital Partners LLC now owns 150,038 shares of the medical instruments supplier’s stock valued at $6,222,000 after acquiring an additional 7,152 shares in the last quarter. Stifel Financial Corp bought a new position in Glaukos Corporation during the 2nd quarter valued at $751,000. Bamco Inc. NY lifted its stake in Glaukos Corporation by 75.7% during the 2nd quarter. Bamco Inc. NY now owns 1,072,246 shares of the medical instruments supplier’s stock valued at $44,466,000 after acquiring an additional 462,019 shares in the last quarter. Finally, Voya Investment Management LLC lifted its stake in Glaukos Corporation by 83.7% during the 2nd quarter. Voya Investment Management LLC now owns 13,123 shares of the medical instruments supplier’s stock valued at $544,000 after acquiring an additional 5,980 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://theolympiareport.com/2017/10/09/glaukos-corporation-gkos-holdings-trimmed-by-fred-alger-management-inc.html.

In other news, CEO Thomas William Burns sold 73,788 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $41.36, for a total transaction of $3,051,871.68. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc sold 325,000 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $37.93, for a total value of $12,327,250.00. The disclosure for this sale can be found here. Insiders sold 980,200 shares of company stock worth $37,900,263 over the last three months. Corporate insiders own 16.40% of the company’s stock.

Several equities analysts have weighed in on GKOS shares. Zacks Investment Research upgraded Glaukos Corporation from a “hold” rating to a “strong-buy” rating and set a $48.00 price objective on the stock in a research note on Tuesday, July 4th. BidaskClub upgraded Glaukos Corporation from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Piper Jaffray Companies restated a “buy” rating and set a $38.00 price objective on shares of Glaukos Corporation in a research note on Friday, September 15th. BMO Capital Markets restated a “buy” rating and set a $54.00 price objective on shares of Glaukos Corporation in a research note on Friday, September 1st. Finally, Stifel Nicolaus restated a “buy” rating on shares of Glaukos Corporation in a research note on Thursday, September 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. Glaukos Corporation presently has a consensus rating of “Buy” and an average target price of $49.86.

Shares of Glaukos Corporation (NYSE GKOS) opened at 33.635 on Monday. The stock’s market capitalization is $1.16 billion. Glaukos Corporation has a 12 month low of $28.72 and a 12 month high of $52.49. The stock’s 50 day moving average price is $34.14 and its 200 day moving average price is $34.14.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.